A176750 Share Price Performance
₩5,650.00
-4610.00 (-44.93%)
43.5% undervalued intrinsic discount
₩10,000.00
Fair Value
Price ₩5,650.00
AnimalDoctorKwon ₩10,000.00
Fair Value₩10,000.00
Share Pricen/a
DuChemBIO Co.,Ltd. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
A176750 Community Narratives
AN
Fair Value
·Fair Value ₩10k 43.5% undervalued intrinsic discount
DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.
DuChemBio (KOSDAQ: 176750): Radiopharmaceutical Monopoly, Radio DNS Labs Merger, and the 6-Month RLT Time Lag 1. The Narrative Origin: From Diagnostic Monopoly to Novartis-Driven RLT Powerhouse DuChemBio is South Korea’s undisputed leader in radiopharmaceuticals.Read more
AN
₩10k
43.5% undervalued intrinsic discount
Fair Value
Revenue
20.6% p.a.
Profit Margin
17.52%
Future PE
22.96x
Price in 2031
₩14.41k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.
Fair Value: ₩10k 43.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
DuChemBIO Co.,Ltd. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- 246.06
- 37.95%
- 17.52%
- 11.8%
About A176750
- Founded
- 2002
- Employees
- 126
- CEO
- WebsiteView website
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease. The company also offers FES, a solution for diagnosis of metastatic breast cancer and determination of estrogen receptor status; FACBC for prostate cancer diagnosis; FDG for the diagnosis of tumors; and NaF for the diagnosis of bone-related diseases. DuChemBIO Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.